Freshworks Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Freshworks Inc trades at $13.54 (market cap $3.62B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.3× Freshworks Inc's market cap, and Hinge Health Inc. Class A Common Stock is more actively traded (879,799 versus 4,303,742). Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FRSH | HNGE | |
|---|---|---|
Market Cap | $3.62B | $8.48B |
Volume | 4,303,742 | 879,799 |
Sector | Technology | Health |
52-Week High | $13.92 | $105.14 |
52-Week Low | $6.88 | $31.17 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.99B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.69, down 1.65% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved GAAP profitability in Q2 2026, with revenue growth of 16% year-over-year and a net income margin of 20.49%. Analyst consensus is split evenly between Buy and Hold, with a price target of $14.60, suggesting modest upside from current levels. Recent news highlights AI adoption and enterprise growth as key drivers.
The outlook for FRSH is positive, supported by sustained revenue growth, improving profitability, and strategic focus on AI and employee experience products. Risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for investors seeking exposure to a profitable, growing software company with a reasonable valuation.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →